Posters

We presented a one-pot reaction to prepare site-specific ADCs using available mABs on hand without re-engineering. We have identified a novel non-cleavable linker, which increases not only ADC stability, but also potency. We also demonstrate synergy in cancer cell killing of hybrid ADC loaded with two different toxins

Development of ADC and other therapeutic proteins require careful characterization of sequence, post-translational modifications, sequence variants, and degradants. In this study, a NIST mAb interim reference material was analyzed by new bioinformatics tools (Byonic™, Byologic®, and Byomap™) allowing one to efficiently identify and quantify modifications down to trace levels.

Drug discovery of natural compounds drug development and drug target analyses as well as bioproduction can benefit from artificial genetic systems and constructions. The direction in which genes are to be developed is written in the genomes. Synthesis oriented genomic analyses of codon bias and tRNA adaption analyses are prerequisites for generating adaptive, highly functional genes.

A new generation PRINT nanoparticle Pneumococcal vaccine matrix has been designed to mimic size and structural aspects of bacterial pathogens to efficiently present and deliver polysaccharide and protein antigens to elicit robust immune responses.

The ability of a drug candidate to induce an unwanted immune response can be a significant hurdle during drug development and a reason for product failures. Unwanted immunogenicity can cause loss of efficacy, altered pharmacodynamics and stability problems. .

MAB Discovery GmbH developped a highly integrated process which provides diverse antibodies by starting with a high number of B cells and filtering the relevant antibodies by an early-on functional screening.

Monoclonal antibodies (Mab) are used in a variety of fields from diagnostics to therapeutics. Manufacturers of in vitro diagnostics (IVD) commonly use third-party suppliers to meet their needs for specified monoclonal antibodies.